Effect of intranasal administration of Semliki Forest virus recombinant particles expressing interferon-β on the progression of experimental autoimmune encephalomyelitis

Molecular Medicine Reports

Volumn 1, Issue 3, 2008, Pages 335-342

  Quinn, K ^a,c   Galbraith, S E ^a,b,d   Sheahan, B J ^b   Atkins, G J ^a  

^a School of Genetics and Microbiology   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

Author keywords

Demyelination; Experimental autoimmune encephalomyelitis; Semliki forest virus vector; interferon

Indexed keywords

BETA INTERFERON; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; VIRUS VECTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN; C57BL 6 MOUSE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; OLFACTORY BULB; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SEMLIKI FOREST ALPHAVIRUS; SPINAL CORD; VIRUS INHIBITION; WEIGHT REDUCTION;

MURINAE; MUS; RABBIT FIBROMA VIRUS; SEMLIKI FOREST VIRUS;

EID: 56349135909     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.1.3.335     Document Type: Article

References (28)

1. Lundstrom K: Alphavirus vectors for vaccine production and gene therapy. Expert Rev Vaccines 2: 447-459, 2003. (Pubitemid 36713370)
2. Atkins GJ, Smyth JW, Fleeton MN, Galbraith SE and Sheahan BJ: Alphaviruses and their derived vectors as anti-tumor agents. Curr Cancer Drug Targets 4: 597-607, 2004.
3. Ehrengruber MU, Renggli M, Raineteau O, Hennou S, Vaha-Koskela MJ, Hinkkanen AE and Lundstrom K: Semliki Forest virus A7(74) transduces hippocampal neurons and glial cells in a temperature-dependent dual manner. J Neurovirol 9: 16-28, 2003. (Pubitemid 36372542)
4. Vaha-Koskela MJ, Tuittila MT, Nygardas PT, Nyman JK, Ehrengruber MU, Renggli M and Hinkkanen AE: A novel neurotropic expression vector based on the avirulent A7(74) strain of Semliki Forest virus. J Neurovirol 9: 1-15, 2003. (Pubitemid 36372541)
5. Jerusalmi A, Morris-Downes MM, Sheahan BJ and Atkins GJ: Effect of intranasal administration of Semliki Forest virus recombinant particles expressing reporter and cytokine genes on the progression of experimental autoimmune encephalomyelitis. Mol Ther 8: 886-894, 2003. (Pubitemid 38072301)
6. Vähä-Koskela MJ, Kuusinen TI, Holmlund-Hampf JC, Furu PT, Heikkilä JE and Hinkkanen AE: Semliki Forest virus vectors expressing transforming growth factor beta inhibit experimental autoimmune encephalomyelitis in Balb/c mice. Biochem Biophys Res Commun 355: 776-781, 2007.
7. Balluz IM, Glasgow GM, Killen HM, Mabruk MJ, Sheahan BJ and Atkins GJ: Virulent and avirulent strains of Semliki Forest virus show similar cell tropism for the murine central nervous system but differ in the severity and rate of induction of cytolytic damage. Neuropathol Appl Neurobiol 19: 233-239, 1993.
8. Sammin DJ, Butler D, Atkins GJ and Sheahan BJ: Cell death mechanisms in the olfactory bulb of rats infected intranasally with Semliki forest virus. Neuropathol Appl Neurobiol 25: 236-243, 1999. (Pubitemid 29313228)
9. Smerdou C and Liljestrom P: Two-helper RNA system for production of recombinant Semliki Forest virus particles. J Virol 73: 1092-1098, 1999. (Pubitemid 29036760)
10. Broberg E, Setala N, Roytta M, et al: Expression of interleukin-4 but not of interleukin-10 from a replicative herpes simplex virus type 1 viral vector precludes experimental allergic encephalomyelitis. Gene Ther 8: 769-777, 2001. (Pubitemid 32509790)
11. Furlan R, Poliani PL, Marconi PC, et al: Central nervous system delivery of interleukin 4 by a nonreplicative herpes simplex type 1 viral vector ameliorates autoimmune demyelination. Human Gene Ther 9: 2605-2617, 1998. (Pubitemid 29004633)
12. Graham A, Walker R, Baird P, Hahn CN and Fazakerley JK: CNS gene therapy applications of the Semliki Forest virus 1 vector are limited by neurotoxicity. Mol Ther 13: 631-635, 2006. (Pubitemid 43257632)
13. Segal BM: CNS chemokines, cytokines and dendritic cells in autoimmune demyelination. J Neurol Sci 228: 210-214, 2005.
14. Skundric DS: Experimental models of relapsing-remitting multiple sclerosis: current concepts and perspective. Curr Neurovasc Res 2: 349-362, 2005. (Pubitemid 41297372)
15. Khoury SJ, Hancock WW and Weiner HL: Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with down-regulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med 176: 1355-1364, 1992.
16. Samoilova EB, Horton JL and Chen Y: Acceleration of experimental autoimmune encephalomyelitis in interleukin-10-deficient mice: roles of interleukin-10 in disease progression and recovery. Cell Immunol 188: 118-124, 1998.
17. Young DA, Lowe LD, Booth SS, et al: IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J Immunol 164: 3563-3572, 2000.
18. Xiao BG, Bai XF, Zhang GX and Link H: Suppression of acute and protracted-relapsing experimental allergic encephalomyelitis by nasal administration of low-dose IL-10 in rats. J Neuroimmunol 84: 230-237, 1998. (Pubitemid 28248411)
19. Xu LY, Huang YM, Yang JS, van der Meide PH, Link H and Xiao BG: Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clin Exp Immunol 120: 526-531, 2000. (Pubitemid 30365560)
20. Cua DJ, Hutchins B, La Face DM, Stohlman SA and Coffman RL: Central nervous system expression of IL-10 inhibits autoimmune encephalomyelitis. J Neuroimmunol 166: 602-608, 2001. (Pubitemid 32038483)
21. Piccirillo CA and Prud'homme GJ: Prevention of experimental allergic encephalomyelitis by intramuscular gene transfer with cytokine-encoding plasmid vectors. Hum Gene Ther 10: 1915-1922, 1999.
22. Sjoberg EM, Suomalainen M and Garoff H: A significantly improved Semliki Forest virus expression system based on translation enhancer segments from the viral capsid gene. Biotechnology 12: 1127-1131, 1994. (Pubitemid 2150244)
23. Chikkanna-Gowda CP, Sheahan BJ, Fleeton MN and Atkins GJ: Regression of mouse tumours and inhibition of metastases following administration of a Semliki Forest virus vector with enhanced expression of IL-12. Gene Ther 12: 1253-1263, 2005.
24. Barbero P, Verdun E, Bergui M, et al: High-dose, frequently administered interferon beta therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the interferon beta dose-reduction study. J Neurol Sci 222: 13-19, 2004. (Pubitemid 38881501)
25. Ruuls SR, De Labie MC, Weber KS, et al: The length of treatment determines whether IFN-β prevents or aggravates experimental autoimmune encephalomyelitis in Lewis rats. J Immunol 157: 5721-5731, 1996.
26. Triantaphyllopoulos KA, Croxford JL, Baker D and Chernajovsky Y: Cloning and expression of murine IFN-β and a TNF antagonist for gene therapy of experimental allergic encephalomyelitis. Gene Ther 5: 253-263, 1998. (Pubitemid 28077754)
27. Ross TM, Martinez PM, Renner JC, Thorne RG, Hanson LR and Frey WH: Intranasal administration of interferon beta bypasses the blood-brain barrier to target the central nervous system and cervical lymph nodes: a non-invasive treatment strategy for multiple sclerosis. J Neuroimmunol 152: 66-77, 2004.
28. Van der Meide PH, De Labie MC, Ruuls SR, et al: Discontinuation of treatment with IFN-β leads to exacerbation of experimental encephalomyelitis in Lewis rats. Rapid reversal of the anti-proliferative activity of IFN-β and excessive expansion of autoreactive T cells as disease promoting mechanisms. J Neuroimmunol 84: 14-23, 1998.